Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes

Launched by GENETESIS INC. · May 28, 2019

Keywords

ClinConnect Summary

This is a single-center, prospective, observational cohort trial to form a registry data set. Patients presenting for cardiac stress testing utilizing Single Photon Emission Computed Tomography (SPECT), cardiac CT angiography (CCTA), or cardiac catheterization will be offered to enroll in the registry and provide informed consent to undergo imaging with a CardioFlux magnetocardiography (MCG) prior to their procedure.

Multiple studies have shown that MCG accuracy is quite high in identifying patients with symptomatic coronary artery disease. This difference is dramatic enough to prove super...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥ 18 years of age at the time of enrollment.
• • Patient presenting for cardiac stress testing, cardiac CT angiography (CCTA), or cardiac catheterization.
• • Consents to having an magnetocardiogram-CardioFlux study scan.
• Exclusion Criteria:
• • \< 18 years of age
• • Patients unable to fit into device
• • Non-ambulatory patients
• • Patients with implanted cardiac pacemakers/defibrillators
• • Positive response on provided Metallic/Ferromagnetic Device Screening Form
• • Atrial fibrillation with rapid ventricular response
• • Patients with other sustained or incessant arrhythmias
• • Patients with claustrophobia or unable to lie supine for 2 minutes
• • Patients require supplemental oxygen at home
• • Presence or reasonable clinical suspicion of any acute coronary syndrome for which delayed intervention could increase the risk or magnitude of damaged myocardium
• • Patients scheduled for cardiac catheterization with indication of valvular disease
• • Poor candidate for follow-up (e.g. no access to phone)
• • Prisoners
• • Repeat participants
• • Patients participate in other research studies